Condition: Solid Tumor, Adult · Sponsor: Egle Therapeutics
This multicenter, open-label, first-in-human, Phase 1/2 study consists of a Part 1 (Phase 1) open-label dose escalation of EGL-001 administered as a single agent and in combination with an anti-PD(L)-1 treatment, followed by a Part 2 (Phase 2) open-label dose expansion of EGL-001 administered at the RP2D in patients with recurrent and/or metastatic solid tumors as monotherapy and/or combination therapy with anti-PD(L)-1.
This description comes directly from the study's public registry record.
Pejvack Motlagh, MD · 33660462343 · contact@egle-tx.com
Always discuss trial participation with your own doctor first.
| Centr Georges Francois Leclerc | Dijon, France | Not Yet Recruiting |
| Institut Regional Du Cancer De Montpellier | Montpellier, France | Recruiting |
| Institut Curie | Paris, France | Recruiting |
| Institut Gustave Roussy | Paris, France | Not Yet Recruiting |
| Hospital Universitari Vall D Hebron | Barcelona, Spain | Not Yet Recruiting |
| Hospital Universitario Fundacion Jimenez Diaz | Madrid, Spain | Not Yet Recruiting |
| Clinica Universidad De Navarra | Pamplona, Spain | Not Yet Recruiting |
| Hospital Clinico Universitario De Valencia | Valencia, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06622486